GlassScriptPhysician profile
Linh Mcclure
NPI 1033623269
$10,136.56
in general payments reported to CMS, 2019-2025
26 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,645 · 2022: $2,005 · 2023: $3,424 · 2024: $2,931 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,487.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,965.02 | 2021-2025 | Enbrel, Otezla, Evenity |
| Janssen Biotech, INC. | $1,491.87 | 2021-2024 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $1,096.96 | 2021-2025 | |
| Ucb, INC. | $843.06 | 2021-2024 | Cimzia, Bimzelx |
| Pfizer INC. | $681.02 | 2021-2024 | |
| Glaxosmithkline, LLC. | $555.74 | 2022-2024 | Benlysta, Nucala |
| Lilly USA, LLC | $544.22 | 2021-2024 | Taltz |
| Horizon Therapeutics Plc | $411.20 | 2021-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $362.50 | 2022-2024 | Saphnelo |
| Aurinia Pharma U.S., INC. | $355.54 | 2022-2024 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $264.90 | 2021-2024 | Acthar |
| Ani Pharmaceuticals, INC. | $245.81 | 2022-2024 | Purified Cortrophin Gel |
| Sobi, INC | $158.71 | 2021-2024 | |
| Genentech USA, INC. | $155.57 | 2023-2024 | Evrysdi, Actemra |
| Ferring Pharmaceuticals INC. | $125.46 | 2022-2024 | Euflexxa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $122.90 | 2021-2024 | Orencia |
| Genzyme Corporation | $121.95 | 2021-2023 | |
| Idorsia Pharmaceuticals US INC | $118.81 | 2023 | Quviviq |
| Paratek Pharmaceuticals, INC. | $116.43 | 2023 | Nuzyra |
| Neurocrine Biosciences, INC. | $108.82 | 2023 | Ingrezza |
| Radius Health, INC. | $94.37 | 2021-2024 | |
| Kiniksa Pharmaceuticals International, Plc | $67.70 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.43 | 2023-2024 | Cyltezo |
| Kiniksa Pharmaceuticals, LTD. | $37.79 | 2023 | Arcalyst |
| Aimmune Therapeutics, INC. | $21.13 | 2025 | Zenpep |
| Alexion Pharmaceuticals, INC. | $15.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linh Mcclure listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.